Tags
It is not known whether Ervebo, licensed only against the Zaire species of Ebola virus, protects people against the Bundibugyo virus behind Kenya's first imported case, WHO said in its outbreak notice of 28 August; the Phase Ib trial of Oxford's Bundibugyo-specific vaccine that began in Uganda on 6 October tests safety, not protection.
On 6 October 2026, the first volunteers in Uganda received a University of Oxford vaccine candidate against Bundibugyo Ebola, in a trial testing its safety and immune response, the MRC/UVRI & LSHTM Uganda Research Unit and Africa CDC said.
On 6 October, Kenya's Director-General for Health, Patrick Amoth, said the country's first Ebola patient may have taken medicine to lower his temperature and pass airport screening, Citizen Digital reported; WHO gave screening and contact figures the same day.
Under a 21 May circular, Kenya checks all arriving travellers for fever and requires an electronic health form from those coming from DR Congo and Uganda; on 6 October WHO advised against travel restrictions.
On 6 October Kenya notified the World Health Organization (WHO) of a confirmed case of Bundibugyo ebolavirus, a species with no licensed vaccine. CEPI said on 1 June that no Bundibugyo vaccine was in clinical development; by 23 July Oxford's candidate was in a Phase 1 trial, Gavi reported, and on 7 August WHO experts recommended a trial of Ervebo, the licensed vaccine for the Zaire species.
